No Data
Piper Downgrades Zimmer to Neutral, Cites Lack of Catalysts
Assessing Johnson & Johnson's Performance Against Competitors In Pharmaceuticals Industry
Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target
Johnson & Johnson Analyst Ratings
Express News | U.S. Food and Drug Administration (FDA) Approves Foundationone Liquid Cdx as a Companion Diagnostic for Akeega (Niraparib and Abiraterone Acetate) for Patients With Brca-Positive Metastatic Castration-Resistant Prostate Cancer
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Cuts Target Price to $167
Morgan Stanley analyst Terence Flynn maintains $Johnson & Johnson(JNJ.US)$ with a hold rating, and adjusts the target price from $168 to $167.According to TipRanks data, the analyst has a success rate